Français Néerlandais Japonais Chinois Allemand Espagnol Portugais

Lille’s Macopharma uses cell therapy to fight diabetes

07 Apr 2015 | Health Nutrition, A region on the move

Lille-based Macopharma, a major specialist player in pharmaceuticals, has developed an automated culturing system to optimize preservation of pancreatic islets—cells that play a key role in treating diabetes.

Macopharma innovation - Health- Lille Region

Prisma—a pioneer in diabetes therapy

Macopharma’s revolutionary Prisma (Pancreatic Islet System Automate unit) breaks new ground in biotherapy.  The product of four years of R&D, this new machine automatically preserves pancreatic islets, the insulin-secreting cells that are used to treat patients with type 1 diabetes.

Patented technology, bold commercial roll-out

Prisma uses three patented systems: a disposable medical device, a cell chamber that preserves the islets, and a specially optimized cell culture medium. “We’ve already deployed Prisma at three major cell therapy centers,” says Bruno Delorme, head of Biotherapy R&D at Macopharma. “These are Lille’s University Hospital Center (CHRU), our co-developer, plus units in Switzerland and in Sweden.

 

 

Source: Les Echos, Nicole Buyse

 

 

Back to news

News

Agricultural transition: BASF invests €6M in Hauts-de-France

As the company renews its product ranges, more warehouse and logistics space is needed at the Gravelines site. This move is part of an overall strategy to transition to agroecology.

Verescence: a €60M investment in Hauts-de-France

London-based Stirling Square acquired a stake in the company at the start of the year, invest-ing €122M in the Verescence 2022 project. €60M of this is destined for its historic Mers-les-Bains site in...

All news